Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLRB Cellectar Biosciences

Market Closed 11-13 16:00:00 EST

1.14

-0.02

-1.72%

盘后1.16

+0.02+1.75%

19:30 EST

High1.21	Low1.13	Vol19.46K
Open1.19	D1 Closing1.16	Amplitude6.47%
Mkt Cap11.44M	Tradable Cap10.94M	Total Shares10.04M
T/O22.36K	T/O Rate0.20%	Tradable Shares9.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences","latestPrice":1.14,"timestamp":1794603600000,"preClose":1.16,"halted":0,"volume":19464,"hourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.14,"latestTime":"19:30 EST","volume":192,"amount":220.74,"timestamp":1794616202143,"change":0.02,"changeRate":0.017544,"amplitude":0.017544},"delay":0,"changeRate":-0.017241379310344845,"floatShares":9595336,"shares":10039200,"eps":-2.708103,"marketStatus":"Market Closed","change":-0.02,"latestTime":"11-13 16:00:00 EST","open":1.19,"high":1.205,"low":1.13,"amount":22361.0548488,"amplitude":0.064655,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.708103,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1794819600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.16,"preHourTrading":{"tag":"盘前","latestPrice":1.19,"preClose":1.16,"latestTime":"09:29 EST","volume":1979,"amount":2303.4900993,"timestamp":1794580199999,"change":0.03,"changeRate":0.025862,"amplitude":0.050603},"postHourTrading":{"tag":"盘后","latestPrice":1.16,"preClose":1.14,"latestTime":"19:30 EST","volume":192,"amount":220.74,"timestamp":1794616202143,"change":0.02,"changeRate":0.017544,"amplitude":0.017544},"volumeRatio":0.2855784636512492,"impliedVol":1.1856,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/CLRB","defaultTab":"news","newsList":[{"id":"2683548359","title":"Sutro Biopharma Q3 Revenue Misses Estimates on Astellas Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2683548359","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683548359?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:40","pubTimestamp":1794519641,"startTime":"0","endTime":"0","summary":"Sutro Biopharma Q3 revenue misses estimates on Astellas collaborationOverviewUS oncology biotech's Q3 revenue declined and missed analyst expectationsCompany posted a net loss for Q3 2026Q3 operating ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1JJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STRO","RCKT","BK4139","CLRB","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683102510","title":"Dyadic Q3 Revenue Falls on Lower Grant Activity","url":"https://stock-news.laohu8.com/highlight/detail?id=2683102510","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683102510?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:30","pubTimestamp":1794519058,"startTime":"0","endTime":"0","summary":"Dyadic Q3 revenue falls on lower grant activityOverviewUS biotechnology firm's Q3 revenue fell 61% yr/yr as grant and R&D revenue declinedCompany's Q3 net loss narrowed from prior year, helped by lowe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1H5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DYAI","LQDA","CLRB","BK4139","LU1878469433.USD","ALT","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683951059","title":"Spero Therapeutics Q3 Net Loss Widens on SP001 Licensing Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2683951059","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683951059?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:24","pubTimestamp":1794518687,"startTime":"0","endTime":"0","summary":"Spero Therapeutics Q3 net loss widens on SP001 licensing paymentOverviewUS biopharma firm's Q3 revenue fell to zero from $5.4 mln a year earlierNet loss for Q3 widened to $44.3 mln, mainly due to $35 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","ALT","BK4007","CLRB","LQDA","SPRO","BK4599","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683510356","title":"Crescent Biopharma Q3 Net Loss Widens Beyond Expectations on Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2683510356","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683510356?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:22","pubTimestamp":1794518575,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Q3 net loss widens beyond expectations on higher R&D expensesOverviewU.S. oncology developer's Q3 net loss widened beyond analysts' expectationsOperating loss for Q3 also missed ana","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1HY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBIO","CLRB","BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683096517","title":"ProKidney Q3 Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2683096517","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683096517?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:18","pubTimestamp":1794518325,"startTime":"0","endTime":"0","summary":"ProKidney Q3 loss widens on higher R&D costsOverviewU.S. cell therapy firm's Q3 net loss widened as R&D and G&A expenses increasedCompany ended Q3 with $142 mln in cash and marketable securities, supp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T1HJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","BK4139","PROK","CLRB","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682599702","title":"Biotech Firm Imunon's Q3 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2682599702","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682599702?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:16","pubTimestamp":1794489416,"startTime":"0","endTime":"0","summary":"Biotech firm Imunon's Q3 net loss widensOverviewUS biotech firm's Q3 net loss widened yr/yr as operating expenses remained steadyCompany reduced outstanding debt by 43% via debt-for-equity exchange in","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T0PT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNN","CLRB","BK4535","CHRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682599186","title":"UK-US MeiraGTx Q3 Net Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2682599186","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682599186?lang=en_us&edition=fundamental","pubTime":"2026-11-12 21:09","pubTimestamp":1794488986,"startTime":"0","endTime":"0","summary":"UK-US MeiraGTx Q3 net loss widens as R&D costs riseOverviewUK-U.S. genetic medicines firm's Q3 revenue rose on increased service revenue from collaborationsQ3 net loss widened slightly to $51.3 mln fr","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T0Q4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","MGTX","BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682562408","title":"Belite Bio Q3 Loss Widens on Higher Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2682562408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682562408?lang=en_us&edition=fundamental","pubTime":"2026-11-12 19:08","pubTimestamp":1794481684,"startTime":"0","endTime":"0","summary":"Belite Bio Q3 loss widens on highercostsOverviewUS retinal drug developer's Q3 net loss widened yr/yr on higher R&D and SG&A costsCompany's lead drug tinlarebant granted FDA priority review for Starga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL2N46T0IW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IONS","OCUL","BLTE","BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682587367","title":"SeaStar Medical Q3 Net Revenue Rises on Quelimmune Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2682587367","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682587367?lang=en_us&edition=fundamental","pubTime":"2026-11-12 05:15","pubTimestamp":1794431703,"startTime":"0","endTime":"0","summary":"SeaStar Medical Q3 net revenue rises on QUELIMMUNE adoptionOverviewHealthcare device maker's Q3 net revenue rose yr/yr on higher QUELIMMUNE adoptionCompany posted Q3 net loss of $4.5 mln as R&D expens","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261111:nL2N46S0WX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4563","BK4082","IRD","BK4139","CLRB","ICU","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682316556","title":"Cellectar Biosciences Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2682316556","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682316556?lang=en_us&edition=fundamental","pubTime":"2026-11-10 22:31","pubTimestamp":1794321101,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences Inc reports results for the quarter ended September 30 - Earnings SummaryCellectar Biosciences IncCLRB.OQreported a quarterly adjusted loss of 46 cents per share for the quarter ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nL5N46R1P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682975543","title":"Cellectar Biosciences - Had Cash and Cash Equivalents of $24.60 Mln as of Sept 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2682975543","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682975543?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:15","pubTimestamp":1794312901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nPLX0FHVZP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682919392","title":"Cellectar Biosciences Q3 EPS USD -0.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2682919392","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682919392?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:15","pubTimestamp":1794312901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nPLX0FHVZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682392916","title":"Cellectar Biosciences Q3 Net Income USD -8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2682392916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682392916?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:15","pubTimestamp":1794312901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nPLX0FHVZP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682929153","title":"Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2682929153","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682929153?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:15","pubTimestamp":1794312900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nTUA4KTLHV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682394237","title":"Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2682394237","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682394237?lang=en_us&edition=fundamental","pubTime":"2026-11-10 20:01","pubTimestamp":1794312113,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses of $(1.41) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/63082762/cellectar-biosciences-q3-eps-0-46-beats-0-56-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680003052","title":"Cellectar Reports Durable Responses to Iopofosine I 131 in Phase 2b Waldenström Macroglobulinemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2680003052","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680003052?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:03","pubTimestamp":1793801010,"startTime":"0","endTime":"0","summary":"Cellectar reports durable responses to iopofosine I 131 in Phase 2b Waldenstrm macroglobulinemia trialCellectar Biosciences will present three iopofosine I 131 posters in Waldenstrm macroglobulinemia ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL7Nq8v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2210150020.SGD","LU2210149790.SGD","BK4139","IE00BN0W2W23.USD","IE00BQXX3D17.EUR","NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","IE00B64PRP62.GBP","IE00BQXX3F31.USD","SG9999014039.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BN0W2T93.GBP","LU2095319765.USD","BK4588","IE00BGHQF748.EUR","BK4585","IE00BQXX3C00.GBP","BCDF","CLRB","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680757425","title":"Cellectar BioSciences to Report Third-Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2680757425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680757425?lang=en_us&edition=fundamental","pubTime":"2026-11-02 21:05","pubTimestamp":1793624715,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences to Report Third-Quarter Financial ResultsCellectar Biosciences will report third-quarter results for the period ended Sept. 30, 2026, on Nov. 10, 2026.A conference call and webca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDLZ1xZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014013.SGD","LU2095319765.USD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585","SG9999014039.USD","BCDF","IE00B64PRP62.GBP","IE00BQXX3F31.USD","IE00BKPKM429.USD","BK4588","SG9999014005.SGD","IE00BQXX3C00.GBP","BK4139","CLRB","IE00BN0W2W23.USD","LU2210150020.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679233666","title":"Cellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenström Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2679233666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679233666?lang=en_us&edition=fundamental","pubTime":"2026-10-30 03:42","pubTimestamp":1793302946,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences Presents Phase 3 Trial Plan for Iopofosine in Waldenstrm MacroglobulinemiaCellectar BioSciences plans to submit an FDA accelerated approval application for iopofosine I 131 in Wa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL8c0Bd3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678117998","title":"Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More than Eight Years in Heavily Pretreated Dlbcl Patient Treated with Iopofosine I 131","url":"https://stock-news.laohu8.com/highlight/detail?id=2678117998","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678117998?lang=en_us&edition=fundamental","pubTime":"2026-10-27 19:15","pubTimestamp":1793099700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nTUA8FVLFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLRB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677612843","title":"Cellectar BioSciences Presents Phase 3 Confirmatory Trial Plans for Iopofosine in Waldenström's Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2677612843","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677612843?lang=en_us&edition=fundamental","pubTime":"2026-10-21 06:24","pubTimestamp":1792535041,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences Presents Phase 3 Confirmatory Trial Plans for Iopofosine in Waldenstrm's MacroglobulinemiaCellectar BioSciences plans to submit a US accelerated approval application for iopofosi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nNDL8HxT4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLRB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":-0.088},{"period":"1month","weight":-0.0339},{"period":"3month","weight":-0.5615},{"period":"6month","weight":-0.6311},{"period":"1year","weight":-0.6028},{"period":"ytd","weight":-0.6136}],"compareEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":-0.0198},{"period":"3month","weight":-0.0283},{"period":"6month","weight":0.0206},{"period":"1year","weight":0.1225},{"period":"ytd","weight":0.1062}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.017624},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024048},{"month":3,"riseRate":0.5,"avgChangeRate":-0.034403},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094306},{"month":5,"riseRate":0.416667,"avgChangeRate":0.057843},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.0753},{"month":7,"riseRate":0.25,"avgChangeRate":-0.094568},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.014253},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.043384},{"month":10,"riseRate":0.076923,"avgChangeRate":-0.174016},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.06218},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.062943}],"exchange":"NASDAQ","name":"Cellectar Biosciences","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cellectar Biosciences(CLRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cellectar Biosciences,CLRB,Cellectar Biosciences股票,Cellectar Biosciences股票老虎,Cellectar Biosciences股票老虎国际,Cellectar Biosciences行情,Cellectar Biosciences股票行情,Cellectar Biosciences股价,Cellectar Biosciences股市,Cellectar Biosciences股票价格,Cellectar Biosciences股票交易,Cellectar Biosciences股票购买,Cellectar Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences(CLRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cellectar Biosciences(CLRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}